Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions

2.8 / 5 stars · 68/120 Roast Me

EDITAS MEDICINE, INC. Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions

EDITAS MEDICINE, INC. (EDIT) reported Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.

Financial Statements › Notes › Income Taxes › Income Tax Uncertainties

us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-09

  • EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2025 was $0.00.
  • EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2023 was $478.00K, a 95.26% decline from fiscal 2022.
  • EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2022 was $10.09M.
Period endUnrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions 12 month
2025-12-31$0.00
10-K · filed 2026-03-09
2024-12-31$0.00
10-K · filed 2026-03-09
2023-12-31$478.00K
10-K · filed 2024-02-28
2022-12-31$10.09M
10-K · filed 2023-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30